Immix Biopharma, Inc. (IMMX)


-0.08 (-4.21%)
Symbol IMMX
Price $1.82
Beta 0.000
Volume Avg. 0.20M
Market Cap 25.347M
Shares () -
52 Week Range 0.68-3.45
1y Target Est -
DCF Unlevered IMMX DCF ->
DCF Levered IMMX LDCF ->
ROE -134550.49% Strong Sell
ROA -140200.35% Strong Sell
Operating Margin -
Debt / Equity 3.86% Neutral
P/E -1.03 Sell
P/B 1.51 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest IMMX news

Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
NASDAQ Capital Market

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.